skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Refined by: Database: ProQuest Central remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
Material Type:
Article 		Add to My Research

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study

Arthritis research & therapy, 2018-05, Vol.20 (1), p.99-99, Article 99 [Peer Reviewed Journal]

COPYRIGHT 2018 BioMed Central Ltd. ;Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. ;The Author(s). 2018 ;ISSN: 1478-6362 ;ISSN: 1478-6354 ;EISSN: 1478-6362 ;DOI: 10.1186/s13075-018-1593-0 ;PMID: 29848361

Full text available

Citations Cited by
2
The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
Material Type:
Article 		Add to My Research

The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study

Rheumatology and therapy., 2023-10, Vol.10 (5), p.1277-1295 [Peer Reviewed Journal]

The Author(s) 2023 ;2023. The Author(s). ;The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2198-6576 ;EISSN: 2198-6584 ;DOI: 10.1007/s40744-023-00581-x ;PMID: 37460856

Full text available

Citations Cited by
3
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
Material Type:
Article 		Add to My Research

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

The New England journal of medicine, 2018-03, Vol.378 (13), p.1200-1210 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1710895 ;PMID: 29527974

Full text available

Citations Cited by
4
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder
Material Type:
Article 		Add to My Research

A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder

Journal of child and adolescent psychopharmacology, 2022-03, Vol.32 (2), p.98-106 [Peer Reviewed Journal]

Copyright Mary Ann Liebert, Inc. Mar 2022 ;Ann C. Childress et al. 2022; Published by Mary Ann Liebert, Inc. 2022 Ann C. Childress et al. ;ISSN: 1044-5463 ;EISSN: 1557-8992 ;DOI: 10.1089/cap.2021.0138 ;PMID: 35230142

Full text available

Citations Cited by
5
Cardiovascular Safety of Febuxostat
Cardiovascular Safety of Febuxostat
Material Type:
Article 		Add to My Research

Cardiovascular Safety of Febuxostat

The New England journal of medicine, 2018-10, Vol.379 (16), p.1582-1584 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc1809736 ;PMID: 30332566

Full text available

Citations Cited by
6
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline
Material Type:
Article 		Add to My Research

The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline

International journal of clinical pharmacology and therapeutics, 2012-05, Vol.50 (5), p.331-337 [Peer Reviewed Journal]

ISSN: 0946-1965 ;DOI: 10.5414/CP201648 ;PMID: 22541837

Full text available

Citations Cited by
7
Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation: Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies
Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation: Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies
Material Type:
Article 		Add to My Research

Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation: Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies

Clinical drug investigation, 2009, Vol.29 (1), p.35-50 [Peer Reviewed Journal]

Adis Data Information BV 2009 ;Copyright Wolters Kluwer Health Adis International 2009 ;ISSN: 1173-2563 ;EISSN: 1179-1918 ;DOI: 10.2165/0044011-200929010-00004 ;PMID: 19067473

Full text available

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait